Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib

Leuk Lymphoma. 2017 Dec;58(12):2969-2972. doi: 10.1080/10428194.2017.1318437. Epub 2017 May 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use
  • Biopsy
  • Bone Marrow / pathology
  • Chromosomal Proteins, Non-Histone / genetics*
  • Chromosome Banding
  • Dasatinib / therapeutic use*
  • Humans
  • Immunohistochemistry
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Male
  • Nuclear Pore Complex Proteins / genetics*
  • Nuclear Proteins / genetics*
  • Oncogene Proteins / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Poly-ADP-Ribose Binding Proteins / genetics*
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor, Platelet-Derived Growth Factor beta / genetics*
  • Receptors, Cytoplasmic and Nuclear / genetics*
  • Repressor Proteins / genetics*
  • Translocation, Genetic
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Chromosomal Proteins, Non-Histone
  • DEK protein, human
  • NUP214 protein, human
  • Nuclear Pore Complex Proteins
  • Nuclear Proteins
  • Oncogene Proteins
  • Oncogene Proteins, Fusion
  • Poly-ADP-Ribose Binding Proteins
  • Protein Kinase Inhibitors
  • Receptors, Cytoplasmic and Nuclear
  • Repressor Proteins
  • TBL1XR1 protein, human
  • PDGFRB protein, human
  • Receptor, Platelet-Derived Growth Factor beta
  • Dasatinib